LAUSR

AD: atopic dermatitis EN: erythema nodosum IL: interleukin INTRODUCTION Dupilumab is a fully human monoclonal antibody that functions as an interleukin (IL) 4a receptor antagonist, inhibiting the activity of both IL-4 and IL13, drivers of T helper 2 mediated inflammation. Although injection-site reactions are the most reported side effect, there have been several reported cases of adverse dermatologic reactions, including facial and neck erythema. We present a case of a patient with severe eosinophilic asthma and chronic sinusitis with nasal polyps in whom drug-induced erythema nodosum (EN) developed after 8 weeks of dupilumab therapy.